Table 1.
Effect of cAMP analogs and PDE inhibitors on L. donovani promastigotes.
| cAMP-analogs/PDE-inhibitors | (EC50 OD600) (µM) | (EC50 MTT) (µM) |
|---|---|---|
| 8-pCPTcAMP | 218.22 ± 37.24 | 200.34 ± 47.9 |
| Sp-8-pCPTcAMPS | 189.78 ± 29.01 | 250.23 ± 34.4 |
| Etazolate | 24.68 ± 6.31 | 89.23 ± 12.9 |
| Dipyridamole | 61.30 ± 11.71 | 112.33 ± 8.45 |
| Trequinsin | 79.59 ± 6.11 | 101.5 ± 15.56 |
| Rolipram | 29.04 ± 4.22 | 123.12 ± 20.05 |
| EHNA | 100.63 ± 14.63 | 156.77 ± 14.60 |
| Zaprinast | 265.15 ± 15.54 | 147.80 ± 14.9 |
EC50 OD600) was calculated after allowing the promastigotes to grow in the presence of analogs/inhibitors for 96 h. (EC50 MTT) was tested by MTT based vital assay after exposing the promastigotes to the analogs and inhibitors for 24 h. Data are representative of at least three independent experiments.